ZO skin suit
This article was originally published in The Rose Sheet
Executive Summary
Prescription skin care firm Obagi Medical Products' motion to dismiss anti-competitive claims by ZO Skin Health was rejected by a Los Angeles County Superior Court in a written opinion July 26, ZO Skin Health announces July 27. A trial date is set for February 2011. In denying OMP's motion, the court stated that "the moral blame attached to the defendant's conduct sufficiently relates to violating laws of free competition" and "the closeness of the connection between the defendant's conduct and the injury suffered is clear." ZO Skin Health, which markets dermatologist Dr. Zein Obagi's retail skin care products, filed suit in January challenging OMP's practices, including efforts to prevent ZO from marketing a new non-prescription skin care line (1"The Rose Sheet" Jan. 11, 2010, In Brief). Obagi founded Worldwide Products Distribution, a firm that later formed the core of OMP, in 1988
You may also be interested in...
Former Obagi Medical Products majority shareholder sues
ZO Skin Health Inc. has filed suit in California Superior Court against Obagi Medical Products, alleging anti-competitive practices. ZO founder Dr. Zein Obagi says OMP, which markets prescription-only skin care, is preventing ZO from marketing a new non-prescription anti-aging skin-care line, citing non-compete clauses. Obagi, a dermatologist, founded Worldwide Products Distribution Inc. in 1988, which would later "form the core" of prescription skin care pharmaceutical firm OMP. In 1997, Obagi sold a controlling share in OMP to a private equity firm, which took the company public. According to a release from Del Mar, Calif.-based ZO, Obagi offered OMP the option to market and distribute his new line, but the firm declined. OMP then "engage[d] in a far-reaching and legally improper campaign" to prevent the line's sale, and also stopped the sale of ZO to a Japanese pharmaceutical firm, claiming it would violate a non-compete clause. However, ZO maintains that clause is unenforceable
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.